Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.

Loddick SA, Ross SJ, Thomason AG, Robinson DM, Walker GE, Dunkley TP, Brave SR, Broadbent N, Stratton NC, Trueman D, Mouchet E, Shaheen FS, Jacobs VN, Cumberbatch M, Wilson J, Jones RD, Bradbury RH, Rabow A, Gaughan L, Womack C, Barry ST, Robson CN, Critchlow SE, Wedge SR, Brooks AN.

Mol Cancer Ther. 2013 Sep;12(9):1715-27. doi: 10.1158/1535-7163.MCT-12-1174. Epub 2013 Jul 16.

2.

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.

Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM.

Neoplasia. 2016 Jan;18(1):1-9. doi: 10.1016/j.neo.2015.11.009.

3.

Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.

Dondoo TO, Fukumori T, Daizumoto K, Fukawa T, Kohzuki M, Kowada M, Kusuhara Y, Mori H, Nakatsuji H, Takahashi M, Kanayama HO.

Anticancer Res. 2017 Jan;37(1):125-134.

PMID:
28011482
4.

Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.

Gowda PS, Deng JD, Mishra S, Bandyopadhyay A, Liang S, Lin S, Mahalingam D, Sun LZ.

Mol Cancer Res. 2013 Nov;11(11):1448-61. doi: 10.1158/1541-7786.MCR-13-0278. Epub 2013 Aug 29.

5.

Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.

Patki M, Huang Y, Ratnam M.

Biochem Biophys Res Commun. 2016 Jul 22;476(2):69-74. doi: 10.1016/j.bbrc.2016.05.058. Epub 2016 May 12.

6.

Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.

Graham L, Schweizer MT.

Med Oncol. 2016 May;33(5):44. doi: 10.1007/s12032-016-0759-3. Epub 2016 Apr 4. Review.

PMID:
27042852
7.

PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells.

Itsumi M, Shiota M, Yokomizo A, Takeuchi A, Kashiwagi E, Dejima T, Inokuchi J, Tatsugami K, Uchiumi T, Naito S.

J Mol Endocrinol. 2014 Aug;53(1):31-41. doi: 10.1530/JME-13-0303. Epub 2014 Apr 29.

PMID:
24780839
8.

Intracrine androgen biosynthesis in renal cell carcinoma.

Lee GT, Han CS, Kwon YS, Patel R, Modi PK, Kwon SJ, Faiena I, Patel N, Singer EA, Ahn HJ, Kim WJ, Kim IY.

Br J Cancer. 2017 Mar 28;116(7):937-943. doi: 10.1038/bjc.2017.42. Epub 2017 Mar 2.

10.

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.

Mol Cancer Ther. 2013 Nov;12(11):2342-55. doi: 10.1158/1535-7163.MCT-13-0032. Epub 2013 Aug 21.

11.

Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.

Nakata D, Nakayama K, Masaki T, Tanaka A, Kusaka M, Watanabe T.

Prostate. 2016 Dec;76(16):1536-1545. doi: 10.1002/pros.23238. Epub 2016 Jul 30.

PMID:
27473672
12.

Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain.

Hua Y, Azeem W, Shen Y, Zhang S, Olsen JR, Øyan AM, Ke X, Zhang W, Kalland KH.

Pharmacol Res Perspect. 2018 Nov 5;6(6):e00437. doi: 10.1002/prp2.437. eCollection 2018 Dec.

13.

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.

Lallous N, Leblanc E, Munuganti RS, Hassona MD, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns ES, Rennie PS, Cherkasov A.

Mol Cancer Ther. 2016 Dec;15(12):2936-2945. Epub 2016 Oct 7.

14.

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.

Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, McEwan IJ, Plymate S, Sadar MD.

Clin Cancer Res. 2016 Sep 1;22(17):4466-77. doi: 10.1158/1078-0432.CCR-15-2901. Epub 2016 May 2.

15.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674. Epub 2013 Jun 13.

PMID:
23765603
16.

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.

Zhang Y, Castaneda S, Dumble M, Wang M, Mileski M, Qu Z, Kim S, Shi V, Kraft P, Gao Y, Pak J, Sapra P, Bandaru R, Zhao H, Vessella RL, Horak ID, Greenberger LM.

Mol Cancer Ther. 2011 Dec;10(12):2309-19. doi: 10.1158/1535-7163.MCT-11-0329. Epub 2011 Oct 25.

17.

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.

Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC.

Clin Cancer Res. 2014 Jun 15;20(12):3198-3210. doi: 10.1158/1078-0432.CCR-13-3296. Epub 2014 Apr 16. Erratum in: Clin Cancer Res. 2017 Jan 1;23 (1):323.

18.

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.

Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18.

19.

NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.

Yu C, Wu G, Li R, Gao L, Yang F, Zhao Y, Zhang J, Zhang R, Zhang J, Yao L, Yuan J, Li X.

Cancer Biol Ther. 2015;16(2):287-96. doi: 10.1080/15384047.2014.1002348.

20.

Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.

Masoodi KZ, Eisermann K, Yang Z, Dar JA, Pascal LE, Nguyen M, O'Malley K, Parrinello E, Feturi FG, Kenefake AN, Nelson JB, Johnston PA, Wipf P, Wang Z.

Endocrinology. 2017 Oct 1;158(10):3152-3161. doi: 10.1210/en.2017-00408.

Supplemental Content

Support Center